Molbio Diagnostics Eyes ₹940 Crore Through IPO Amid Global Expansion

Molbio Diagnostics is launching an initial public offering (IPO) to raise ₹940 crore, with a dual focus on expanding capital expenditures and reducing promoter stake. The company targets ₹200 crore from a fresh issue of shares and an additional ₹740 crore through an offer for sale. This move will lower the promoter group's ownership from 46.6% to 43%.

Strategic Growth and Global Reach

Founded in 2000, Molbio Diagnostics has established itself in the molecular diagnostics sector, with six manufacturing facilities across India. The company serves a broad international market, reaching over 90 countries, and partners with government health programs, diagnostic labs, and healthcare organizations globally. A significant portion of its revenue stems from its tuberculosis diagnostic test kits, which are a key product in its portfolio.

The company's proprietary 'Truenat' platform, a portable diagnostic system, is designed to deliver quick results in resource-constrained settings. This innovation supports over 30 disease tests through 43 diagnostic assays, and Molbio extends its services into radiology, digital pathology, and breast health screening through various subsidiaries and partnerships.

Financial Performance and Market Position

Molbio has demonstrated robust financial growth, with revenue from operations increasing by 31.5% annually, reaching ₹1,445.7 crore between FY24 and FY26. The net profit for the same period rose by 40.2% to ₹164.1 crore. The company's EBITDA also saw a 33.2% increase, hitting ₹328.2 crore, while the EBITDA margin slightly improved to 22.6% in FY26.

On a year-on-year basis, the company's revenue surged by 41.7% in FY26. Despite the lack of direct competitors in India, Molbio's valuation places it alongside notable healthcare diagnostics and medical device firms like Poly Medicure and Dr. Lal PathLabs, with a price-earnings (P/E) ratio up to 57, comparable to their P/E multiples of 54 to 81.

Investment Considerations

Molbio Diagnostics primarily earns its revenues from government and international aid agencies, which contribute over 80% of its income. The company's reliance on a few top clients for more than half of its revenue highlights a potential risk factor. However, its consistent financial growth and strategic expansion into global markets may appeal to investors with a high-risk appetite seeking long-term growth opportunities.